乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

SABCS

<乌鸦传媒>Oral SERD Tops Fulvestrant for PFS in ER-Positive Breast Cancer

Camizestrant also led to meaningful PFS improvements in those with detectable ESR1 mutations

<乌鸦传媒>Continuing CDK4/6 Inhibitor Beyond Progression No Help in Metastatic Breast Cancer

Prior therapy, baseline mutations confound results; "intriguing" benefit with PD-L1 inhibitor

<乌鸦传媒>Pausing Endocrine Therapy for Pregnancy Safe in Early Breast Cancer

Study suggests no increased risk of cancer recurrence versus historical control

<乌鸦传媒>T-DXd Continues Winning Streak in Metastatic, HER2-Positive Breast Cancer

Trastuzumab deruxtecan improves survival in second- and later-line settings

<乌鸦传媒>Neoadjuvant T-DXd Active in HER2-Low Breast Cancer

Response rates on the order of 58-68%, with or without endocrine therapy

<乌鸦传媒>Everolimus Fails Again as Adjuvant Therapy for High-Risk Breast Cancer

No improvement in the overall analysis but a hint of benefit in premenopausal patients

<乌鸦传媒>Assay Predicts Breast Cancer Patients Who Will Benefit From Ovarian Suppression

Low score suggests improved outcomes with ovarian suppression plus adjuvant endocrine therapy

<乌鸦传媒>First-Line CDK4/6 Thumps Chemo in Aggressive, Advanced Breast Cancer

Doubling of PFS could be death knell for combination chemotherapy in difficult-to-treat subgroup

<乌鸦传媒>Metastasis 'Doorway' May Lead to Racial Disparities in Breast Cancer

Density of cellular complex after neoadjuvant therapy tied to cancer subtypes, may be targetable

<乌鸦传媒>Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancer

No clear explanation for responses to HER2-targeted drug in HER2-negative tumors

<乌鸦传媒>Neratinib-Based Combo Shows Efficacy in HR+, HER2-Mutant Metastatic Breast Cancer

Objective response rate of 42% in patients previously treated with CDK4/6 inhibitors

<乌鸦传媒>'Watch and Switch' Strategy Extends PFS in HR-Positive Breast Cancer

Progression-free survival doubled with treatment change based on monitoring for resistance marker

<乌鸦传媒>CDK7 Inhibitor-Based Combo Promising in CDK4/6-Resistant Breast Cancer

Clinical benefit rate of 36%, plus tumor shrinkage, with samuraciclib plus fulvestrant

<乌鸦传媒>Pyrotinib Tops Lapatinib in Metastatic HER2-Positive Breast Cancer

Updated PHOEBE trial results now show an overall survival benefit as well

<乌鸦传媒>Benefits of Ovarian Suppression Persist in Premenopausal Breast Cancer

Aromatase inhibitor-ovarian suppression tops tamoxifen strategies at 12-13 years

<乌鸦传媒>Highly Mutated Breast Cancer Responds to Immunotherapy

Nivolumab-ipilimumab combination associated with durable response in small study

<乌鸦传媒>Ribociclib's OS Benefit in Breast Cancer Seen Regardless of Metastatic Site

Second analysis shows OS benefit consistent across some intrinsic subtypes as well

<乌鸦传媒>No Benefit With Metformin in Early Breast Cancer, Regardless of ER/PR Status

However, there could be improved outcomes in HER2-positive patients

<乌鸦传媒>Small PFS Boost With HDAC Inhibitor for Advanced HR-Positive Breast Cancer

Chinese study contradicts U.S. trial that showed no benefit with entinostat add-on

<乌鸦传媒>Black Women Most at Risk for Post-Surgical Lymphedema

Black women seemed to have triple the odds of swelling after axillary lymph node dissection

<乌鸦传媒>TROP2-Directed ADC Promising in Advanced Triple-Negative Breast Cancer

Datopotamab deruxtecan turns in solid phase I results

<乌鸦传媒>Genomic Profiling Improves Outcomes in Breast Cancer

PFS was better when targeted treatment for genomic alterations was supported by ESCAT criteria

<乌鸦传媒>Novel Endocrine Drug Slows Previously Treated HR-Positive Breast Cancer

Elacestrant led to significant improvement in all patients, ESR1-mutant subgroup

<乌鸦传媒>Add-On HDAC Inhibitor No Help in Breast Cancer

PFS, OS similar to endocrine therapy alone for advanced HR+ disease

<乌鸦传媒>Online Tool Refines Individual Risks in Breast Cancer

RSClin incorporates 21-gene recurrence score with tumor grade, size, and more

<乌鸦传媒>Doctor-Patient Discord in Reporting Radiation Toxicity

Physicians underrecognized substantial symptoms in more than half of patients

<乌鸦传媒>Adjuvant Palbociclib Fails in Early, High-Risk Breast Cancer

No iDFS benefit with 1 year of CDK4/6 inhibition following neoadjuvant chemotherapy

<乌鸦传媒>Oral Paclitaxel Bests IV Delivery in Advanced Breast Cancer

But high pill count, lengthy dosing schedule could prove to be problematic

<乌鸦传媒>Residual Breast Cancer Tool Highly Prognostic After Neoadjuvant Tx

Tumor burden calculator predicted long-term outcomes in all breast cancer subtypes

<乌鸦传媒>Anti-CDK4/6 Fails to Top Chemo in HR-Positive MBC

Similar PFS with chemo, palbociclib plus exemestane or fulvestrant after progression on aromatase inhibitor

<乌鸦传媒>HRT Has 20-Year Impact on Breast Cancer Risks

Prospective data confirm long-term benefit with estrogen-only and harm with added progestin

<乌鸦传媒>Checkpoints Show Different Outcomes in Breast Cancer

Atezolizumab misses complete response benefit in triple negative patients

<乌鸦传媒>T-DM1 Falls Short as Less-Toxic Option for Early Breast Cancer

Promising efficacy but higher discontinuation rates and cost likely a deterrent

<乌鸦传媒>Edging Closer to OS Benefit With Novel Anti-HER2 Drug

Larger benefit with margetuximab in most common HER2 breast cancer phenotype

<乌鸦传媒>Late-Line HER2 Drug Impresses in Metastatic Breast Cancer

Median PFS over three times better than what is typically seen in this setting, says investigator

<乌鸦传媒>New Standard for Metastatic HER2 Breast Cancer

Consistent PFS, OS benefit with combination including oral HER2 inhibitor tucatinib

<乌鸦传媒>Patients Say Quality of Life Suffered With Mastectomy for Early Breast Cancer

Breast-conservation options were associated with better sexual, psychosocial outcomes

<乌鸦传媒>SABCS: Axillary RT as Good as Surgery in Breast Cancer

Radiation non-inferior to surgery after positive sentinel node

<乌鸦传媒>Low-Dose Tamoxifen Feasible Option in Breast Cancer

Women appear to prevent recurrence in early stage cancers with 5 mg dosing

<乌鸦传媒>Xeloda Disappoints in Early Triple-Negative Breast Cancer

No improvement after standard chemo, though subset may derive some benefit

1